Gastroesophageal Reflux Disease
Gastrointestinal 0 original drugsGastrointestinal indication. Gastroesophageal Reflux Disease has 0 FDA-approved novel treatments across 2 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Phase 3 Readouts Pro
1 active Phase 3 trial with confidence-graded completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Gastroesophageal Reflux Disease Treatments by Mechanism
Top 2 mechanisms across 18 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Gastroesophageal Reflux Disease Clinical Pipeline by Phase
97 industry-sponsored trials across 40 sponsors
Novel Gastroesophageal Reflux Disease Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (8 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Gastroesophageal Reflux Disease Drug Targets
Molecular targets of approved and investigational Gastroesophageal Reflux Disease drugs — 2 targets tracked.
Generic Drugs (6 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs